Abstract

Due to advances in disease-modifying medications and earlier management of comorbidities, adults with multiple sclerosis (MS) are living longer, and this coincides with the aging of the general population. One major problem among older adults with and without MS is limited mobility, a consequence of aging that often negatively affects quality of life. Identifying factors that contribute to mobility disability is needed to develop targeted rehabilitation approaches. This study examined cognitive processing speed and global brain atrophy as factors that may contribute to mobility disability in older adults with and without MS. Older adults (≥55 years) with MS (n = 31) and age- and sex-matched controls (n = 22) completed measures of mobility (Short Physical Performance Battery) and cognitive processing speed (Symbol Digit Modalities Test) and underwent an MRI to obtain whole-brain metrics (gray matter volume, white matter volume, ventricular volume) as markers of atrophy. Mobility was significantly worse in the MS group than in the control group (p = 0.004). Spearman correlations indicated that neither cognitive processing speed (MS: rs = 0.26; Control: rs = 0.08) nor markers of global brain atrophy (MS: rs range = −0.30 to −0.06; Control: rs range = −0.40 to 0.16) were significantly associated with mobility in either group. Other factors such as subcortical gray matter structures, functional connectivity, exercise/physical activity, and cardiovascular fitness should be examined as factors that may influence mobility in aging adults with and without MS.

Highlights

  • multiple sclerosis (MS), a mean disease duration of 18.3 (6.1) years, and moderate disability based on a median

  • The current study examined the influence of central factors on mobility in older adults with MS and a sample of age- and sex-matched healthy older adults

  • Our results suggest that neither cognitive processing speed nor global measures of brain atrophy influenced mobility in older adults with or without MS

Read more

Summary

Introduction

There are an estimated 1 million adults living with multiple sclerosis (MS) in the United States (US), and 43% of them are 55 years of age or older [1]. This reflects an age-related shift in the prevalence of people with MS associated with the “greying” of the general US population and major advances in disease-modifying medications that extend life expectancy in MS. The life expectancy of adults with MS (75.9 years) is reportedly 7.5 years less than that of adults without a chronic neurological disease (83.4 years) [2]

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call